MedTrace Logo

This Study Is To Estimate The Time Course Of Pf-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers

NCT01272375 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2018-12-03

No results posted yet for this study

Summary

The purpose of this study is to investigate the time course of PF-04764793 concentration in the blood following dosing by oral inhalation from dry powder inhalers.

Conditions

  • Healthy

Interventions

DRUG

Treatment A

PF-04764793 250/50 using inhaler A

DRUG

Treatment B

PF-04764793 250/50 using inhaler A

DRUG

Treatment C

PF-04764793 250/50 using inhaler A

DRUG

Treatment D

PF-04764793 250/50 using inhaler A

DRUG

Treatment E

PF-04764793 250/50 using inhaler B

DRUG

Treatment F

PF-04764793 250/50 using inhaler B

DRUG

Treatment G

PF-04764793 250/50 using inhaler B

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01272375 on ClinicalTrials.gov